# verisimlife.com

> AI-optimized mirror of verisimlife.com containing 180 pages totalling 176,950 words of clean markdown content, structured data, and semantic HTML. Original source: https://verisimlife.com. Last updated: 2026-07-25T09:13:00.365Z.

Each page is available as HTML (with JSON-LD structured data) and Markdown (text-only, ideal for LLMs and RAG).

## Homepage

- [VeriSIM Life | AI Drug Discovery & Development](/content/site-root.html): Make confident decisions about drug development, quickly and efficiently, using a decision-engine that takes your toughest translational questions and generate actionable insights to guide your next steps. (365 words)

## Articles & Blog Posts

- [Not Found](/content/our-platformr/index.html) (28 words)
- [VeriSIM Life Founder & CEO Dr. Jo Varshney Named to Inc.’s Female Founders 500 for Advancing Predictive Drug Development │ Drug Discovery & Development Technology](/content/press-events/verisim-life-founder-ceo-dr-jo-varshney-named-to-inc-s-female-founders-500-for-advancing-predictive-drug-development.html) (681 words)
- [VeriSIM Life Wins Gold for Most Innovative Company of the Year in Annual Stevie® Awards for Women in Business │ Drug Discovery & Development Technology](/content/press-events/verisim-life-wins-gold-stevie-awards-for-women-in-business.html): San Francisco, CA – November 11, 2024 – VeriSIM Life, a pioneer in AI-driven drug development, is thrilled to announce it has won a Gold Stevie® Award for Most Innovative Company of the Year in the Stevie Awards for Women in Business. The Stevie Awards are widely recognized as the premier business accolades worldwide, celebrating the outstanding achievements of women leaders, entrepreneurs, and companies they lead. Dr. Jo Varshney founded VeriSIM Life in 2017 to transform the drug development landscape, and this honor reflects the company’s commitment to bringing life-saving therapies to patients more efficiently. (581 words)
- [VeriSIM Life Named Finalist for Reuters AI in Action Award Category │ Drug Discovery & Development Technology](/content/press-events/verisim-life-named-finalist-for-reuters-ai-in-action-award-category.html): San Francisco, CA – September 8, 2025 – VeriSIM Life, a leading AI-first biotechnology company, today announced it has been named a finalist for the prestigious AI in Action award category in the 2025 Reuters Pharma Awards. This award recognizes organizations and individuals who have demonstrably worked to reduce patient burden, amplify patient communities, and advance the patient voice in pharmaceutical research and development. (507 words)
- [VeriSIM Life Launches AtlasGEN™ Novel Drug Designer │ Drug Discovery & Development Technology](/content/press-events/verisim-life-launches-atlasgen-tm-novel-drug-designer.html): Pharma industry’s first platform to design clinical success into the discovery of new drugs from day one. (568 words)
- [VeriSIM Life Named Finalist for the 2025 Scrip Awards Innovation Category │ Drug Discovery & Development Technology](/content/press-events/verisim-life-named-finalist-for-the-2025-scrip-awards-innovation-category.html): San Francisco, CA – September 22, 2025 – VeriSIM Life, a leading innovator in AI-driven drug development and translational intelligence, is proud to announce that it has been shortlisted as a finalist in the prestigious 2025 Scrip Awards, under the Innovation Award category. (313 words)
- [VeriSIM Life launches PulmoSIM Therapeutics to Develop Treatments for Rare Respiratory Diseases │ Drug Discovery & Development Technology](/content/press-events/verisim-life-launches-pulmosim-therapeutics-to-develop-treatments-for-rare-respiratory-diseases.html) (13 words)
- [Webinar from VeriSIM Life | AI in Drug Development: Hype or Reality?](/content/info/ai-webinar/index.html): This discussion explores how adopting AI and deep technology to the R&D process reduces costs and accelerates time to market whilst maintaining safety.  (139 words)
- [VeriSIM Life Webinar - Using AI in Drug Development to Enhance Preclinical Translatability](/content/info/xtalks-sep1-webinar/index.html): Download this webinar recording to learn how exactly AI and ML techniques are taking computational modeling and informatics to new domains of applicability in the drug development lifecycle. Through illustrative examples of AI in drug development, attendees will gain a better understanding of how these techniques can be applied to enhance decision-making and increase the chances of clinical success. (146 words)
- [newsletter](/content/info/newsletter/index.html): Sign up for the VeriSIM Life newsletter (28 words)
- [Not Found](/content/our-platforrm/index.html) (28 words)
- [Not Found](/content/case-studies/translational-research/index.html) (28 words)
- [VeriSIM Life Wins Prestigious AI in Action Award at Reuters Global Pharma Awards │ Drug Discovery & Development Technology](/content/press-events/verisim-life-wins-prestigious-ai-in-action-award-at-reuters-global-pharma-awards.html): San Francisco, CA — December 3, 2025 — VeriSIM Life, a leading innovator in AI-driven biosimulation and translational intelligence, today announced that it has been named the winner of the AI in Action Award at the 2025 Reuters Global Pharma Awards, an international program recognizing the most impactful advances shaping the future of the life sciences industry. (416 words)
- [VeriSIM Life Named Most Innovative Company Finalist in Stevie® Awards for Women in Business │ Drug Discovery & Development Technology](/content/press-events/verisim-life-most-innovative-company-finalist-stevie-award.html): San Francisco, CA – September 23, 2024 – VeriSIM Life was named a finalist in the Most Innovative Company of the Year category in the 21st annual Stevie® Awards for Women in Business. The Stevie Awards for Women in Business honor women executives, entrepreneurs, employees and the companies they run, worldwide. VeriSIM Life was founded in 2017 by Dr. Jo Varshney. The Stevie Awards have been hailed as the world’s premier business awards. (717 words)
- [VeriSIM Life Secures $15 Million Series A Funding │ Drug Discovery & Development Technology](/content/press-events/verisim-life-secures-15-million-series-a-funding/index.html): Financing led by Morpheus Ventures supports further revenue growth for the company’s next-generation AI platform, redefining the preclinical translational drug development landscape by accurately predicting and accelerating clinical outcomes January 6, 2022–SAN FRANCISCO–(BUSINESS WIRE)–VeriSIM Life (VeriSIM) www.verisimlife.com, the leading artificial intelligence (AI)-enabled, unique… (564 words)
- [VeriSIM Life Partners with Clarivate to Help Researchers Accelerate and De-Risk Drug Development  │ Drug Discovery & Development Technology](/content/press-events/verisim-life-partners-with-clarivate-to-help-researchers-accelerate-and-de-risk-drug-development-2.html): VeriSIM Life (VeriSIM) www.verisimlife.com, the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced a partnership with Clarivate www.clarivate.com, a global leader in connecting people and organizations to intelligence they can trust. (547 words)
- [VeriSIM Life Wins “Machine Learning Platform of the Year” at the 2025 AI Breakthrough Awards │ Drug Discovery & Development Technology](/content/press-events/verisim-life-wins-machine-learning-platform-of-the-year-at-the-2025-ai-breakthrough-awards.html): San Francisco, CA – June 25, 2025 — VeriSIM Life, a leading innovator in AI-powered drug development, today announced that it has been awarded “Machine Learning Platform of the Year” in the 2025 AI Breakthrough Awards. This honor recognizes VeriSIM’s flagship platform, BIOiSIM®, for its unparalleled ability to transform drug discovery through the power of predictive modeling and translational intelligence. (369 words)
- [VeriSIM Life Wins "Best AI-Driven Drug Development Engine 2025 - USA" in GHP Biotechnology & Lifesciences Awards │ Drug Discovery & Development Technology](/content/press-events/verisim-life-wins-best-ai-driven-drug-development-engine-2025-usa-in-ghp-biotechnology-lifesciences-awards.html): San Francisco, CA – April 14, 2025 – VeriSIM Life, a leading innovator in artificial intelligence (AI) for drug development, is proud to announce that it has been honored with the "Best AI-Driven Drug Development Engine 2025 - USA" award at the prestigious Global Health & Pharma (GHP) Biotechnology & Lifesciences Awards. (402 words)
- [VeriSIM Charles Goodwin │ Drug Discovery & Development Technology](/content/advisors/charles-goodwin/index.html): Commercial Advisor (89 words)
- [VeriSIM Alexander Harmsen │ Drug Discovery & Development Technology](/content/advisors/alexander-harmsen/index.html): CEO & Founder of Global Predictions; Chairman & Founder Iris Automation (216 words)
- [VeriSIM Life successfully raises $5.2m USD to avoid unnecessary drug testing in animals during drug development │ Drug Discovery & Development Technology](/content/press-events/verisim-life-successfully-raises-5-2m-usd-to-avoid-unnecessary-drug-testing-in-animals-during-drug-development.html): The global drug discovery market is estimated to be worth at least $35 billion, a figure that could rise to $71 billion by 2025. But taking a drug from research and development to market is a long and resource-intensive process. (17 words)
- [Meet With Us at the J.P. Morgan Healthcare Conference](/content/info/meet-with-us-jpm/index.html) (56 words)
- [VeriSIM Life Secures a Federal Grant to Create a Drug Combinatorial Platform Against COVID-19 │ Drug Discovery & Development Technology](/content/press-events/verisim-life-secures-a-federal-grant-to-create-a-drug-combinatorial-platform-against-covid-19.html) (15 words)
- [VeriSIM Life Founder & CEO Dr. Jo Varshney Named to 2025 "100 Women in AI" List │ Drug Discovery & Development Technology](/content/press-events/verisim-life-founder-ceo-dr-jo-varshney-named-to-2025-100-women-in-ai-list.html): San Francisco, CA – May 13, 2025 – VeriSIM Life, a trailblazer in artificial intelligence (AI)-powered drug development, is proud to announce that its Founder and CEO, Dr. Jo Varshney, has been named to the 2025 “100 Women in AI” list by Flybridge Capital Partners and XFactor Ventures. (332 words)
- [VeriSIM Life Formalizes Research Collaboration with FDA/NCTR, Advancing the Next Generation of Mechanistic AI for Drug Development  │ Drug Discovery & Development Technology](/content/press-events/verisim-life-formalizes-research-collaboration-with-fda-nctr.html): Material Transfer Agreement with FDA establishes a formal framework for collaboration, reinforcing BIOiSIM’s role as a scientifically defensible, mechanistically grounded AI platform designed for the rigor of translational drug development. (391 words)
- [VeriSIM Life 'Ask Me Anything' Webinar ](/content/info/ask-me-anything-webinar/index.html): Rredictive AI and machine learning techniques are filling gaps previously out of reach to traditional approaches. Download this webinar recording with VeriSIM Life CEO & Founder Dr. Jo Varshney and Dr. Jeff Barrett, CSO at Aridhia. (128 words)
- [VeriSIM In Silico Development of Combinatorial Therapeutic Approaches Targeting Key Signaling Pathways in Metabolic Syndrome │ Drug Discovery & Development Technology](/content/publications-blog/in-silico-development-of-combinatorial-therapeutic-approaches-targeting-key-signaling-pathways-in-metabolic-syndrome.html): Originally published in Pharmaceutical Research Purpose Dysregulations of key signaling pathways in metabolic syndrome are multifactorial, eventually leading to cardiovascular events. Hyperglycemia in conjunction with dyslipidemia induces insulin resistance and provokes release of proinflammatory cytokines resulting in chronic inflammation, accelerated… (6,810 words)
- [VeriSIM Pathways for Successful AI Adoption in Drug Development   │ Drug Discovery & Development Technology](/content/publications-blog/pathways-for-successful-ai-adoption-in-drug-development.html): Specific benchmarking practices, the use of Explainable AI and a well-developed technology roadmap are critical success factors to effectively onboard AI/ML for drug development. (3,882 words)
- [VeriSIM Webinar Transcript: Accelerating Clinical Translation of Antibody-Drug Conjugates with Hybrid AI │ Drug Discovery & Development Technology](/content/publications-blog/webinar-transcript-debiopharm/index.html): The following transcript was taken from a recorded conversation between Dr. Jo Varshney, CEO of VeriSIM Life, and Dr. Annick Menetrey, Clinical Pharmacology Lead at Debiopharm. Read on to understand how VeriSIM Life and Debiopharm partnered to scalably investigate first-in-human (FIH) dosing strategies for antibody-drug conjugates to reduce tumor burden safely and effectively. (Edited for clarity and length.) (5,470 words)
- [VeriSIM An AI Approach to Generating MIDD Assets Across the Drug  Development Continuum  │ Drug Discovery & Development Technology](/content/publications-blog/an-ai-approach-to-generating-midd-assets-across-the-drug-development-continuum.html): Applications of Machine Learning and AI to Drug Discovery, Development, and Regulations. Originally published in The AAPS Journal (2023) 25:70 (7,698 words)
- [VeriSIM A hybrid modeling approach for assessing mechanistic models of small molecule partitioning in vivo using a machine learning integrated modeling platform │ Drug Discovery & Development Technology](/content/publications-blog/a-hybrid-modeling-approach-for-assessing-mechanistic-models-of-small-molecule-partitioning-in-vivo-using-a-machine-learning-integrated-modeling-platform.html): Originally published at Nature Scientific Reports Prediction of the first-in-human dosing regimens is a critical step in drug development and requires accurate quantitation of drug distribution. Traditional in vivo studies used to characterize clinical candidate’s volume of distribution are error-prone,… (4,613 words)
- [VeriSIM Knowledge-enhanced AI to Supercharge ADC Development for Treatment of Cancer │ Drug Discovery & Development Technology](/content/publications-blog/knowledge-enhanced-ai-to-supercharge-adc-development-for-treatment-of-cancer.html): The use of Artificial Intelligence (AI) is becoming increasingly prevalent in drug discovery and development and holds the potential to address the challenges in ADC development. AI requires substantial amounts of high-quality data to make reliable predictions of a novel ADC’s safety and efficacy. However, since this therapeutic area is still fairly new, there is limited data available to meet all the challenges of ADC development through AI. In such a scenario, enriching AI with knowledge (hybrid AI) is a very promising approach and provides high-accuracy predictions even in data-limited scenarios. (2,411 words)
- [publications-blog/animal-reduction-methods-and-best-practices/index.html](/content/publications-blog/animal-reduction-methods-and-best-practices/index.html) (1,116 words)
- [Not Found](/content/media-coverage/verisim-delivering-predictive-insights-to-advance-and-de-risk-drug-development.html) (28 words)
- [Not Found](/content/media-coverage/media-coverage-3/index.html) (28 words)
- [Not Found](/content/media-coverage/how-ai-is-transforming-drug-development-jo-varshney-phd-dvm.html) (28 words)
- [Not Found](/content/media-coverage/how-do-we-build-trust-and-transparency-in-ai/index.html) (28 words)
- [Not Found](/content/media-coverage/ai-is-reshaping-drug-discovery-now-it-must-prove-it-can-be-trusted.html) (28 words)
- [Not Found](/content/media-coverage/from-preclinical-to-clinic-faster-with-mechanistic-modeling-and-ai.html) (28 words)
- [Not Found](/content/media-coverage/can-patients-trust-a-drug-designed-by-ai/index.html) (15 words)
- [Not Found](/content/media-coverage/ai-now-develops-drugs-faster-than-humans-is-that-a-good-thing.html) (28 words)
- [VeriSIM Safety in Numbers: Understanding the Effectiveness of Herbals Through Better Science │ Drug Discovery & Development Technology](/content/publications-blog/safety-in-numbers-understanding-the-effectiveness-of-herbals-through-better-science.html): Owing to my Indian roots, herbal medicine has been a part of my everyday life in the form of ayurveda. As a child, I remember my mum making a concoction of holy-basil, mint and liquorice whenever I had a bad… (1,347 words)
- [Not Found](/content/media-coverage/a-future-beyond-animal-testing-why-oriva-matters-and-how-computational-models-bridge-the-gap.html) (28 words)
- [Not Found](/content/media-coverage/how-ai-driven-integration-of-data-improves-preclinical-studies-reduces-drug-trial-failures-jo-varshney-phd-dvm.html) (28 words)
- [Not Found](/content/media-coverage/how-technology-is-moving-the-industry-away-from-animal-testing-q-a-with-dr-jo-varshney.html) (28 words)
- [Not Found](/content/media-coverage/spotlight-on-fdas-one-trial-shift-pushing-risk-upstream.html) (28 words)
- [Not Found](/content/media-coverage/fail-fast-is-not-a-cultural-problem-it-is-a-capital-allocation-problem.html) (28 words)
- [Not Found](/content/media-coverage/a-credit-score-like-risk-assessment-system-for-investigative-drugs.html) (28 words)
- [Not Found](/content/solutions/de-novo-discovery/index.html) (28 words)
- [VeriSIM When It Comes to AI in Drug Development, Should We Believe the Hype? │ Drug Discovery & Development Technology](/content/publications-blog/when-it-comes-to-ai-in-drug-development-should-we-believe-the-hype.html): AI technologies like deep learning, machine learning and natural language processing have the potential to address many of the challenges that traditionally plague drug R&D – accelerating molecule design and testing, streamlining essential processes, improving chances of clinical success, and reducing costs throughout the development pipeline. (719 words)
- [VeriSIM What Is the Translational Gap and How Do You Close It? │ Drug Discovery & Development Technology](/content/publications-blog/what-is-the-translational-gap/index.html): Drug discovery has a translatability problem. The National Institutes of Health (NIH) once famously reported that for every drug that receives FDA approval, another 1,000 fail. In drug development, translatability refers to the basic principle of taking scientific findings from a laboratory setting and successfully translating them as therapeutic patient treatments in a clinical setting. This is sometimes also referred to as the bench-to-bedside process. (986 words)
- [VeriSIM Supercharging QSP with a Comprehensive View of the Drug Development Process │ Drug Discovery & Development Technology](/content/publications-blog/supercharging-qsp-with-a-comprehensive-view-of-the-drug-development-process.html): In the ever-evolving landscape of drug development, scientists are continually seeking innovative approaches to streamline processes, reduce costs, and enhance efficiency. One such approach is Quantitative Systems Pharmacology (QSP) modeling, a multidisciplinary field that integrates mathematics, biology, and pharmacology to facilitate a deeper understanding of the complexities underlying disease and drug response. With the growing prominence of Artificial Intelligence (AI), QSP modeling is poised for transformative advancements that could revolutionize the drug development pipeline. (1,676 words)
- [VeriSIM The Top 5 Challenges in Drug Bioavailability That Can Be Solved by AI │ Drug Discovery & Development Technology](/content/publications-blog/the-top-5-challenges-in-drug-bioavailability-that-can-be-solved-by-ai.html): There are several critical challenges that can affect bioavailability, including solubility, permeability, drug-drug interactions, and metabolic profile. Traditional methods for addressing these challenges are often time-consuming and expensive, but luckily, Artificial intelligence (AI) can act as a powerful tool to overcome these challenges and improve drug bioavailability. (1,536 words)
- [VeriSIM What Is Explainable AI &  How Can It Help in the  Context of Drug Discovery? │ Drug Discovery & Development Technology](/content/publications-blog/what-is-explainable-ai-how-can-it-help-in-the-context-of-drug-discovery.html): XAI is emerging as a methodology that can help improve trust, confidence, and successful adoption of AI-driven approaches – especially in the context of drug discovery. Let’s take a closer look. (906 words)
- [VeriSIM Solving First in Human Dosing Challenges with AI │ Drug Discovery & Development Technology](/content/publications-blog/solving-first-in-human-dosing-challenges-with-ai/index.html): One major difficulty in FIH dosing is considering variability in human response. The complexity of possible individual responses is challenging to account for using traditional FIH dosing methods, and failure to properly consider these possible variations can result in heightened risk of adverse effects in clinical trial participants. It can also increase the already high cost/time investment of clinical trials. This underscores the need for more sophisticated approaches in FIH dosing that can account for the myriad factors that influence individual human response. (1,263 words)
- [VeriSIM Using AI & MIDD to Decode Drug-drug Interactions │ Drug Discovery & Development Technology](/content/publications-blog/using-ai-midd-to-decode-drug-drug-interactions/index.html): Let’s explore how AI-driven approaches to drug development can be used to decode DDIs, why it is important to detect them, as well as how to integrate AI into your strategy of detecting potential DDIs. (1,019 words)
- [VeriSIM VeriSIM Life’s Alignment with Recent FDA Draft Guidelines  │ Drug Discovery & Development Technology](/content/publications-blog/verisim-lifes-alignment-with-recent-fda-draft-guidelines.html): VeriSIM Life's BIOiSIM platform is highly aligned with the core principles of new FDA documents, as it leverages advanced artificial intelligence (AI) and machine learning (ML) approach to simulate complex pharmacokinetics and pharmacodynamics models. This approach ensures robust predictions of drug behavior in diverse patient populations, aligning directly with the guideline's emphasis on physiologically based pharmacokinetics (PBPK) and quantitative systems pharmacology. (624 words)
- [VeriSIM How AI Assists Small Molecule Drug Design and Development │ Drug Discovery & Development Technology](/content/publications-blog/how-ai-assists-small-molecule-drug-design-and-development.html): From identifying novel drug targets to optimizing the manufacturing process, AI is transforming the way small molecule drugs are discovered, designed, and developed. AI-driven drug development holds remarkable potential for accelerating the availability of life-changing therapies through small molecule drug development. Read on to connect the linkages between small molecule drug chemistry, the drug discovery and development process, and the application of AI to deliver safe and effective drugs for clinical use in patients. (1,888 words)
- [VeriSIM Accelerating SUD Therapy Discovery with AI/ML Driven BBB Permeability Predictions │ Drug Discovery & Development Technology](/content/case-studies/accelerating-sud-therapy-discovery-with-ai-ml/index.html): VeriSIM Life partnered with our client to translate drug candidates targeting SUD patient therapies more rapidly and accurately than traditional methods that depend on the experimental uncertainty of modeling for data. (87 words)
- [VeriSIM Synthetic Data in Drug Development - What it is and How it Relates to AI-informed Approaches │ Drug Discovery & Development Technology](/content/publications-blog/synthetic-data-in-drug-development-what-it-is-and-how-it-relates-to-ai-informed-approaches.html): In drug development, researchers are investigating the viability of synthetic data as an alternative to RWD in some of its AI-informed approaches. Let’s take a closer look at how the use of synthetic data is impacting the drug development landscape. (942 words)
- [VeriSIM Pathways for Successful AI Adoption in Drug Development │ Drug Discovery & Development Technology](/content/case-studies/ai-adoption-white-paper/index.html): Artificial intelligence in drug development has transformative potential when it comes to pharma research and development (R&D). Download the white paper to advance the adoption of AI within your organization. (111 words)
- [VeriSIM Patient Stratification: What You Need to Know to Do it Right │ Drug Discovery & Development Technology](/content/publications-blog/patient-stratification/index.html): In today’s complex world, we truly only understand a tiny fraction of biology. When performing clinical trials, scientists/researchers must figure out ways to develop methods to effectively represent a whole with a subset or sampling due to costs and time. These methodologies, when done correctly, are all based on statistical methods. This is true for population genetics and patient stratification for clinical trials and studies. (1,236 words)
- [VeriSIM Mechanistic Models in Theory and in Practice │ Drug Discovery & Development Technology](/content/publications-blog/mechanistic-models-in-theory-and-in-practice/index.html): Mechanistic models serve as a useful candidate for modeling the detailed inner workings of a system in a true-to-life manner, going above and beyond simulating basic input and output. They can be used as a tool to improve preclinical translatability, reduce time and cost investments, and solve real-world problems safely. (1,258 words)
- [VeriSIM Protein Characterization & Identification: What To Know │ Drug Discovery & Development Technology](/content/publications-blog/protein-characterization-identification-what-to-know.html): There are a range of different protein characterization techniques that can be used to detect, isolate and map the unique amino acids that make up a protein chain. (1,071 words)
- [VeriSIM VeriSIM Life Partners on Digital Endpoints Adoption in Clinical Trials │ Drug Discovery & Development Technology](/content/publications-blog/verisim-life-partners-on-digital-endpoints-adoption-in-clinical-trials.html): DATAcc’s’s latest initiative, "Building the Business Case for Digital Endpoints," aims to catalyze investment in digital measurement development and deployment within clinical trials. Through the development of a comprehensive value framework, benchmarking tools, ROI forecasting models, and a modular business case template, both of our organizations strive to empower innovators across the industry to embrace digital endpoints and drive their universal adoption and scalability in clinical research. VeriSIM Life has joined this groundbreaking project as a partner to boost investment and utilization of digital endpoints by equipping decision-makers with tangible data to articulate the value of integrating these strategies into their business operations. (458 words)
- [VeriSIM Overcoming Challenges in Transdermal Formulations: How AI Improves Patient Experience │ Drug Discovery & Development Technology](/content/publications-blog/overcoming-challenges-in-transdermal-formulations-how-ai-improves-patient-experience.html): VeriSIM Life’s BIOiSIM® platform can address the challenges of TD formulation development because its hybrid AI models capture the complex interplay between the API, excipients, and physiology. BIOiSIM uses a unique combination of mathematical and AI-driven techniques to analyze and predict a drug’s behavior in the human body. The platform's models provide deep insight into drug distribution in various skin layers and underlying tissues, such as joint synovial membranes, and capture a drug’s systemic exposure and clearance post-transdermal application. (717 words)
- [VeriSIM University of Toronto Study Confirms What VeriSIM Life Already Knows About the Potential of AI in Drug Development │ Drug Discovery & Development Technology](/content/publications-blog/university-of-toronto-study-confirms-what-verisim-life-already-knows-about-the-potential-of-ai-in-drug-development.html): This discussion around budding research into the benefits of AI and machine learning in drug discovery matters not only because it demonstrates that these topics aren’t going away anytime soon, but that it further validates the ability of AI to predict drug behavior accurately and reduce the time and cost of developing a new drug candidate. (309 words)
- [VeriSIM Molecular Modeling: A Detailed Guide │ Drug Discovery & Development Technology](/content/publications-blog/molecular-modeling-a-detailed-guide/index.html): With the growth of computational capabilities over the last decade, molecular modeling has been called a game changer in drug discovery research and the biopharma industry. (1,046 words)
- [VeriSIM How to Invest in AI to Improve Clinical Trials │ Drug Discovery & Development Technology](/content/publications-blog/how-to-invest-in-ai-to-improve-clinical-trials/index.html): In this blog, we take a look at some specific ways current and emerging AI technologies are poised to improve clinical trials – from processes to patient outcomes – and what to look for when choosing an AI partner or platform. (1,157 words)
- [VeriSIM Implementing a Scaled System for Drug Development │ Drug Discovery & Development Technology](/content/publications-blog/implementing-a-scaled-system-for-drug-development/index.html): Why Scale Matters At VeriSIM Life, we pride ourselves on solving complex problems. After all, we’re working to simulate the entire human body! At the center of our efforts is the BIOiSIM platform: our core simulation technology that accurately predicts… (1,415 words)
- [VeriSIM How AI Enables the Use of Real World Evidence in Drug Development │ Drug Discovery & Development Technology](/content/publications-blog/how-ai-enables-the-use-of-real-world-evidence-in-drug-development.html): Artificial intelligence (AI) has emerged as a game-changer in unlocking the potential of real-world evidence (RWE) to revolutionize the way we design, test, and deliver new treatments. RWE, which encompasses a wealth of data from electronic health records, patient-reported outcomes, and other sources, offers invaluable insights into drug safety and effectiveness in real-world settings. AI is becoming a transformative force in harnessing RWE to improve drug development and for addressing challenges that come with RWE such as data quality, patient privacy, and bias. (1,442 words)
- [VeriSIM How Taking Smart Risks Makes Drug Development Less Speculative │ Drug Discovery & Development Technology](/content/publications-blog/how-taking-smart-risks-makes-drug-development-less-speculative.html): Originally published by Forbes Technology Council. It’s impossible to totally eliminate risk in drug discovery. However, AI-driven approaches and other breakthrough technologies are continually proving their worth, helping create tangible efficiencies and better outcomes for drugmakers. (864 words)
- [VeriSIM AI-Driven Integration of Transcriptomics, Quantum Mechanics, and Physiology for Predicting Drug-Induced Liver Injury in Data-Limited Scenarios │ Drug Discovery & Development Technology](/content/publications-blog/predicting-drug-induced-liver-injury-in-data-limited-scenarios.html): The approach used in the study, especially the incorporation of knowledge-based features to enrich AI models, holds tremendous promise for not only assessing safety and toxicity assessments of drug candidates but also in other aspects such as target engagement and efficacy of these candidates, early in the development phase. (221 words)
- [VeriSIM Parting Thoughts from Fierce@JPM Week LIVE 2023 │ Drug Discovery & Development Technology](/content/publications-blog/parting-thoughts-from-fierce-jpm-week-live-2023/index.html): The 2023 edition of the annual JP Morgan Healthcare conference was eagerly expected after 2 years of “virtual” meetings, and for those fortunate enough to attend, the gathering did not disappoint. While the main event featured headlines from the major pharma companies, we’re happy to report firsthand that events around the edges fostered innovative collaborations and partnerships. Fierce’s JPM Week day at the San Francisco Fairmont was one such venue. Here’s a few hot takes from the day’s presenters and networking chatter. (470 words)
- [VeriSIM Accelerating novel drugs to patients together–how combining discovery and development technologies will transform drug decision making │ Drug Discovery & Development Technology](/content/publications-blog/molomics-and-verisim-transform-drug-decision-making.html): BIOiSIM is a first-in-class decision-making engine that can take your toughest questions and generate answers to guide your next steps at any stage of drug development. With the acquisition of Molomics, it will be powered by one of the largest and fastest growing inferential search spaces in existence, encompassing over 1 trillion compounds. (618 words)
- [VeriSIM How AI can be of Support to Drug Development │ Drug Discovery & Development Technology](/content/publications-blog/how-ai-can-be-of-support-to-drug-development/index.html): We have come a long way in human healthcare – from increasing average life expectancy, to controlling infectious diseases like AIDS and tuberculosis. Despite the acceleration in pharmacological and technological advances over the years that contributed to this success, the… (957 words)
- [VeriSIM Generative AI & Drug Development – What You Need To Know │ Drug Discovery & Development Technology](/content/publications-blog/generative-ai-drug-development-what-you-need-to-know.html): Researchers are beginning to look at the utility of generative AI in drug development for specific ways this particular type of machine learning technology might help streamline, improve, or otherwise accelerate the development of new drugs. Here’s what you need to know about generative AI and drug development. (848 words)
- [VeriSIM Scalable in silico Simulation of Transdermal Drug Permeability: Application of BIOiSIM Platform │ Drug Discovery & Development Technology](/content/publications-blog/scalable-in-silico-simulation-of-transdermal-drug-permeability.html): Transdermal drug delivery is gaining popularity as an alternative to traditional routes of administration. It can increase patient compliance because of its painless and noninvasive nature, aid compounds in bypassing presystemic metabolic effects, and reduce the likelihood of adverse effects through decreased systemic exposure. In silico physiological modeling is critical to predicting dermal exposure for a therapeutic and assessing the impact of different formulations on transdermal disposition. (6,010 words)
- [VeriSIM Life Webinar - AI in Biomedical Research: Regulatory & Technology Perspectives](/content/info/xtalks-oct30-webinar/index.html): Discover a groundbreaking webinar delving into the use of artificial intelligence (AI) and machine learning (ML) in preclinical drug research and related regulatory frameworks. The challenges and opportunities of integrating AI into preclinical drug research and development workflows are of increasing importance, especially in the context of regulatory science expectations. On the one hand, legislative priorities seek to reduce the cost of healthcare and drugs, while also reducing the burden of testing on animals through the use of technology like AI. (134 words)
- [VeriSIM Molecular Simulation and Statistical Learning Methods toward Predicting Drug–Polymer Amorphous Solid Dispersion Miscibility, Stability, and Formulation Design │ Drug Discovery & Development Technology](/content/publications-blog/predicting-drug-polymer-amorphous-solid-dispersion-miscibility-stability-and-formulation-design.html): Amorphous solid dispersions (ASDs) have emerged as widespread formulations for drug delivery of poorly soluble active pharmaceutical ingredients (APIs). Predicting the API solubility with various carriers in the API–carrier mixture and the principal API–carrier non-bonding interactions are critical factors for… (12,234 words)
- [VeriSIM FDA Signals a New Era for Drug Development — VeriSIM Life Is Already There │ Drug Discovery & Development Technology](/content/publications-blog/fda-signals-a-new-era-for-drug-development-verisim-life-is-already-there.html): From the beginning, VSL has pioneered a mission-driven approach rooted in the belief that advanced simulations can replace outdated, animal-centric paradigms that have limited applicability to humans. The FDA now explicitly affirms that AI-based computational modeling can reliably simulate how monoclonal antibodies (mAbs) distribute through the human body, predict side effects based on molecular features, and accelerate therapeutic delivery without compromising safety. That’s exactly what VSL already enables and more! (717 words)
- [VeriSIM Crash Course to Using AI to Determine Dose Selection │ Drug Discovery & Development Technology](/content/publications-blog/crash-course-to-using-ai-to-determine-dose-selection.html): The development of a drug is a complex and lengthy process, requiring precise decisions about dosing to ensure both the efficacy and safety of a drug. Artificial intelligence (AI) can be used for dose selection in drug development—helping to save time, money, and increase accuracy. Before embarking upon this journey, it is important to grasp not only the basics of dose selection and why it’s important in drug development, but also how exactly AI improves the dose selection process. (1,360 words)
- [VeriSIM Dose Optimization: How to Get it Right │ Drug Discovery & Development Technology](/content/publications-blog/dose-optimization-how-to-get-it-right/index.html): At the heart of dose optimization is a mandate to safeguard the health of study participants. From unwanted side effects to reduced efficacy and toxicity, the pharmacological effect of administered doses for any potential drug candidate must always be carefully vetted for safety and efficacy. Let’s take a closer look at dose optimization – what it is and how to get it right. (1,052 words)
- [VeriSIM Gene Expression Profiling: What It Is and How to Do It │ Drug Discovery & Development Technology](/content/publications-blog/gene-expression-profiling-what-it-is-and-how-to-do-it.html): Understanding the why, when and how of gene expression is a complex science. Gene expression profiling gives biomedical researchers a critical tool for developing and testing their hypotheses, helping them form a deeper, more comprehensive picture of cell function and biology. Looking toward the future, emerging applications of RNA-sequencing tools are likely to continue to evolve gene expression profiling – driving the discovery of new disease biomarkers and therapeutic drug targets. (1,104 words)
- [VeriSIM Biosimulation in Depth: A Detailed Guide │ Drug Discovery & Development Technology](/content/publications-blog/biosimulation-in-depth-a-detailed-guide/index.html): Biosimulation, which uses computer simulations of biological processes to predict the behavior of biological systems, is on a significant growth trajectory – thanks in part to the FDA’s strong recommendation for adopting biosimulation, an overall increase in predictive biosimulation in the research and development (R&D) process, and the recent use of biosimulation platforms for the development of COVID-19 vaccines. Now, as pharmaceutical and biotech companies continue to invest in artificial intelligence (AI)-enabled tools and technologies, we should expect to see even more widespread adoption of biosimulation across drug discovery and development. (1,185 words)
- [VeriSIM Enhancing FDA-Approved AI/ML Methods: VeriSIM Life's Comprehensive Approach to Drug Development and Patient Selection │ Drug Discovery & Development Technology](/content/publications-blog/comparing-bioisim-to-fda-reference-standard-for-ai-ml-methods.html): The FDA's development and use of an AI/ML-based scoring rule for patient selection in the Emergency Use Authorization (EUA) of anakinra to treat COVID-19 marks a significant milestone in the integration of advanced technologies in drug development and patient care. This article explores the FDA's approach, its requirements, and how VeriSIM Life's cutting-edge techniques offer an even more informative and powerful methodology for drug development and patient selection. (1,128 words)
- [VeriSIM Animal Experimentation Reduction Methods and Best Practices │ Drug Discovery & Development Technology](/content/publications-blog/animal-experimentation-reduction-methods-and-best-practices.html): Animal experimentation reduction techniques offer a variety of partial solutions to the enduring controversial issue of animal use in scientific research. In the United States alone, The Humane Society estimates that over 50 million animals are used in experiments annually. (1,117 words)
- [VeriSIM Integrating AI/ML Models for  Patient Stratification Leveraging Omics Dataset and Clinical  Biomarkers from COVID-19 Patients │ Drug Discovery & Development Technology](/content/publications-blog/integrating-ai-ml-models-for-patient-stratification-leveraging-omics-dataset.html): In this manuscript, we demonstrate the recent advances and predictive accuracies in AI- and ML-based patient stratification modeling linking omics and clinical biomarker datasets, focusing on COVID-19 patients. (9,490 words)
- [VeriSIM Biomarker Discovery and Validation Explained │ Drug Discovery & Development Technology](/content/publications-blog/biomarker-discovery-and-validation-explained/index.html): Biomarkers play a crucial role in drug development, helping measure the effects of investigational treatments in humans during clinical trials. Recently, advancements in biomarker discovery and validation methods, spurred on by innovations in instrumentation and in silico predictive tools , are improving diagnosis, prognosis and disease monitoring. Let’s take a closer look at biomarker discovery and validation. (1,029 words)
- [VeriSIM Biomarker Discovery: Function and Advancement │ Drug Discovery & Development Technology](/content/publications-blog/biomarker-discovery/index.html): Biomarker Discovery & Validation Biomarker discovery is defined as the process in which biological markers, or “biomarkers” for short, are evaluated and measured. This process begins with defining a biological process and analyzing for different types of biomarkers. These can be prognostic, diagnostic, or predictive to determine treatment efficacy or monitor patient safety. Expanding upon this definition, the World Health Organization defines this term as "almost any measurement reflecting an interaction between a biological system and a potential hazard, which may be chemical, physical, or biological.” Biomarkers are also an integral part of drug development as they help accurately determine drug safety and efficacy. In contemporary medicine, many clinical decisions are based upon laboratory test results. According to the Centers for Disease Control, these tests account for 70% of clinical decisions. (1,176 words)
- [VeriSIM AI-Informed Drug Development & Discovery: Excerpts From a Conversation with FDA Regulatory Science Leadership  │ Drug Discovery & Development Technology](/content/publications-blog/ai-informed-drug-development-discovery-excerpts-from-a-conversation-with-fda-regulatory-science-leadership.html): Hardly a week passes without the press spotlighting the growing attention governments are paying to artificial intelligence (AI). For the pharmaceutical and biotech industries, this has created some confusion. Should the progress made by scientists to integrate AI technology as another method to advance exploration and discovery be reconsidered? Are regulators now more concerned about research supported by AI and ML? Will my investigational new drug application be slowed or rejected if submitted with AI-based research? Read the blog to learn more.l (1,146 words)
- [VeriSIM FDA Modernization Act & What It Means for VeriSIM Life │ Drug Discovery & Development Technology](/content/publications-blog/fda-modernization-act-what-it-means-for-verisim-life.html): The FDA Modernization Act strikes out the language referencing animal testing and introduces, in its place, “non-clinical tests” such as those made possible by AI and data modeling. This change has seen a level of bipartisan support rarely witnessed in legislation today, and it is a critical milestone in the history of R&D in that it supports use of simulation and predictive technologies to increase efficiency and candidate success.VeriSIM Life has been ahead of the curve in recognizing these advantages for five years and counting, pioneering the way towards this inevitable industry change by using technology to help clients increase the efficacy of preclinical testing while taking measures towards “de-risking” the process. (636 words)
- [VeriSIM Getting life-saving therapeutics to patients faster │ Drug Discovery & Development Technology](/content/publications-blog/getting-life-saving-therapeutics-to-patients-faster.html): At the heart of the wave of new technologies to replace animals in research are the biotech companies utilizing modern scientific methods that are fundamentally human, and not derived from animals. (9 words)
- [VeriSIM Using AI in Drug Development to Identify Metabolites & Harness Their Insights │ Drug Discovery & Development Technology](/content/publications-blog/blog-using-ai-in-drug-development-to-identify-metabolites-harness-their-insights.html): This article explores the significance of metabolites in drug development and how artificial intelligence (AI) is revolutionizing metabolite identification, leading to improved drug development outcomes. We will delve into the role of metabolites in drug development, the challenges of metabolite identification, and the benefits of AI-powered metabolite identification. (1,143 words)
- [VeriSIM Chemical Absorption Explained in Simple Terms │ Drug Discovery & Development Technology](/content/publications-blog/chemical-absorption-explained-in-simple-terms/index.html): In pharmacology, absorption is studied as part of drug development and during clinical trials. In this context, absorption is the process by which a drug moves from the delivery site into the bloodstream. (1,047 words)
- [VeriSIM Transcript: AI and Drug Development - Keeping it Real with Pharma │ Drug Discovery & Development Technology](/content/publications-blog/ai-and-drug-development-keeping-it-real-with-pharma.html): The following transcript was taken from a recorded conversation between Dr. Jo Varshney, CEO of VeriSIM Life, and Dr. Grazia Rovelli, Senior Researcher and Project Leader, Italfarmaco Group. Read on to understand how established companies are approaching AI and integrating it into their strategy as well as their research and development workflows. (1,240 words)
- [VeriSIM Does AI Hold the Potential to Reduce Reliance on NHPs in Drug Development? This National Academies of Science, Engineering & Medicine Report Concludes “Yes.” │ Drug Discovery & Development Technology](/content/publications-blog/does-ai-hold-the-potential-to-reduce-reliance-on-nhps-in-drug-development-this-national-academies-of-science-engineering-medicine-report-concludes-yes.html): Non-human primates (NHPs) still hold undeniable value for the pharmaceutical and biotechnology industries, but with ethical and practical issues posing increasing challenges, it is clear that we need a smarter approach to utilizing NHPs. For this reason and in response to a request from Congress, a committee of experts organized by the National Academies of Science, Engineering & Medicine recently released a report on the usage of NHPs in biomedical research. This report's conclusions serve as guidance for subsequent action by the NIH to address the current critical NHP shortage. (480 words)
- [VeriSIM Genentech & VeriSIM discuss present and future scenarios for drug development in pharma │ Drug Discovery & Development Technology](/content/publications-blog/genentech-verisim-discuss-present-and-future-scenarios-for-drug-development-in-pharma.html): They explain how VeriSIM is changing drug discovery and development and why more and more drugs are being developed “in silico.” They also discuss how startups can work in harmony with big companies and how big pharma has become much… (14 words)
- [VeriSIM An In-Depth Guide to Pharmacokinetic Modeling │ Drug Discovery & Development Technology](/content/publications-blog/an-in-depth-guide-to-pharmacokinetic-modeling/index.html): Quantifying how a drug moves into, through, and out of the body is at the heart of pharmacokinetic modeling (PK), helping inform many aspects of the drug development process. (1,016 words)
- [VeriSIM Convergence of AI and Digital Measures for Seamless Preclinical to Clinical Translation │ Drug Discovery & Development Technology](/content/publications-blog/convergence-of-ai-and-digital-measures-for-seamless-preclinical-to-clinical-translation.html): A recent workshop on the "Convergence of AI and Digital Measures for Seamless Preclinical to Clinical Translation" brought together, for the first time, experts from clinical and preclinical into one room to explore the transformative potential of combinatorial power of digital measures and AI technologies in drug development. Through focused sessions and case studies, we explored the current implementation and validation processes for AI/ML-derived digital measures and addressed the challenges and obstacles to their adoption. Our goal was to identify strategies for integrating digital measures and AI to enhance the translation from preclinical to clinical stages, improve data precision, and create a synergistic effect for a comprehensive understanding of these technologies. (759 words)
- [VeriSIM A New Era: Human-First Drug Development │ Drug Discovery & Development Technology](/content/publications-blog/a-new-era-human-first-drug-development/index.html): On July 4, 2025, the National Institutes of Health (NIH) unveiled a groundbreaking policy shift poised to redefine the future of biomedical research. NIH announced that it is moving away from traditional animal-only models and will prioritize cutting-edge, human-based research technologies such as artificial intelligence (AI) that offer greater clinical relevance, precision, and ethical responsibility. (884 words)
- [VeriSIM 50 shades of AI in regulatory science with Dr. Weida Tong from FDA │ Drug Discovery & Development Technology](/content/publications-blog/50-shades-of-ai-in-regulatory-science-with-dr-weida-tong-from-fda.html): Understanding the context-of-use for each AI shade is crucial to address biases, ensure transparency, and enhance decision-making processes within regulatory frameworks. In this article, the authors emphasize the need for tailored regulatory measures to accommodate AI’s diverse roles, ensuring AI enhances rather than complicates regulatory processes. (922 words)
- [VeriSIM VeriSIM Life’s AtlasGEN Novel Drug Designer Bridges the Translational Gap, Bringing Life-Saving Treatments to Patients Faster │ Drug Discovery & Development Technology](/content/publications-blog/atlasgen-novel-drug-designer-bridges-the-translational-gap.html): VeriSIM Life recently announced the availability of AtlasGEN™ Novel Drug Designer, which is the first and only platform that combines generative chemical discovery with biological validation to compress drug candidate selection and reduce costly experimental research dramatically. AtlasGEN is different because it constrains the generative AI with biological data, ensuring relevant and accurate results. Instead of returning 1000 potential molecular hits, most of which are not good, AtlasGEN reduces wasted time, energy and money by returning only the results that are viable. (487 words)
- [VeriSIM Entering the Era of Computationally Driven Drug Development │ Drug Discovery & Development Technology](/content/publications-blog/entering-the-era-of-computationally-driven-drug-development-2.html): Increasing quality and standardization of experimental methods in preclinical testing have created valuable data sets that improve the efficiency and accuracy of preclinical prediction for both pharmacokinetics (PK) and PD. Models of quantitative structure–activity relationships (QSAR), physiologically based pharmacokinetics (PBPK), and PK/PD relationships have also improved efficiency. Founded on a core understanding of biochemistry and physiological interactions of xenobiotics, these in silico methods have the potential to increase the probability of compound success in clinical trials. Integrating machine-learning approaches and new data sets stands to make a fundamental impact on the speed and accuracy of predictions from R&D to approval. (11,185 words)
- [VeriSIM Advancing the Use of Artificial Intelligence In Harmony with Drug Regulation │ Drug Discovery & Development Technology](/content/publications-blog/advancing-the-use-of-artificial-intelligence-in-harmony-with-drug-regulation.html): Recently the FDA released a publication, “Using Artificial Intelligence & Machine Learning in the Development of Drug and Biological Products,” and requested comments on the framework outlined within it from subject matter experts in the industry. VeriSIM Life, which provides a computational drug development platform that uses AI and ML to streamline the drug development process, was eager to contribute our thoughts and feedback to the conversation. (789 words)
- [VeriSIM Accelerated Repurposing and Drug Development of Pulmonary Hypertension Therapies for COVID-19 Treatment Using an AI-Integrated Biosimulation Platform │ Drug Discovery & Development Technology](/content/publications-blog/drug-repurposing-for-covid-19-treatment/index.html): The COVID-19 pandemic has reached over 100 million worldwide. Due to the multi-targeted nature of the virus, it is clear that drugs providing anti-COVID-19 effects need to be developed at an accelerated rate, and a combinatorial approach may stand to… (8,426 words)
- [VeriSIM Effects of Magnesium, Calcium, and Aluminum Chelation on Fluoroquinolone Absorption Rate and Bioavailability: A Computational Study │ Drug Discovery & Development Technology](/content/publications-blog/effects-of-magnesium-calcium-and-aluminum-chelation-on-fluoroquinolone-absorption-rate-and-bioavailability-a-computational-study.html): Fluoroquinolones (FQs) are a widespread class of broad-spectrum antibiotics prescribed as a first line of defense, and, in some cases, as the only treatment against bacterial infection. However, when administered orally, reduced absorption and bioavailability can occur due to chelation… (7,220 words)
- [VeriSIM 3 Ways AI Can Improve the De-Risking of R&D Decisions      │ Drug Discovery & Development Technology](/content/publications-blog/3-ways-ai-can-improve-the-de-risking-of-r-d-decisions.html): There are many possible roadblocks on the path to IND approval using traditional methods of drug discovery and development alone. Adverse drug-drug interactions (DDIs), ineffective drug formulation, and poorly understood patient stratification are among the top. Hurdles like these can represent “blind alleys” invisible when a candidate is initially discovered, that make carrying forward translational research and clinical trials extremely risky. Luckily, the integration of artificial intelligence (AI) into drug development can help in these three core aspects of de-risking R&D decisions and successfully getting a new drug to market. (691 words)
- [Verisimlife](/content/videos/bioisim-a-new-paradigm/index.html) (204 words)
- [Verisimlife](/content/videos/intel-capital-interview-with-verisim-life-ceo-jo-varshney.html) (51 words)
- [Verisimlife](/content/videos/xtalks-oct30-webinar/index.html) (158 words)
- [Verisimlife](/content/videos/using-ai-in-drug-development-to-enhance-preclinical-translatability.html) (200 words)
- [Verisimlife](/content/videos/ask-me-anything-mitigating-translational-risk-with-ai-enabled-midd.html) (173 words)
- [VeriSIM Life Named "Predictive Analytics Solution of the Year" at BioTech Breakthrough Awards for Second Consecutive Year │ Drug Discovery & Development Technology](/content/press-events/verisim-life-named-predictive-analytics-solution-of-the-year-at-biotech-breakthrough-awards-for-second-consecutive-year.html): VeriSIM Life announces recognition for continued advances with BIOiSIM, a first-in-class virtual drug development engine. (742 words)
- [VeriSIM Jeff Barrett, PhD │ Drug Discovery & Development Technology](/content/advisors/jeff-barrett-phd/index.html): Former VP Sanofi, Bill & Melinda Gates Research Institute, FDA Advisory Committee (406 words)
- [Verisimlife](/content/videos/ai-in-drug-development-hype-or-reality/index.html) (131 words)
- [Verisimlife](/content/videos/accelerating-clinical-translation-of-antibody-drug-conjugates-with-hybrid-ai.html) (318 words)
- [Verisimlife](/content/videos/ai-and-drug-development-keeping-it-real-with-pharma.html) (117 words)
- [VeriSIM Rick Sax, MD │ Drug Discovery & Development Technology](/content/advisors/rick-sax-md/index.html): Former VP, QuintilesIMS, AstraZeneca (201 words)
- [FCOI Policy](/content/fcoi-policy/index.html): VeriSIM Life FCOI Policy (4,149 words)
- [VeriSIM AI-Generated Virtual Patients Enhance Clinical Trial Outcomes: a Diabetes Treatment Analysis │ Drug Discovery & Development Technology](/content/case-studies/ai-generated-virtual-patients/index.html): VeriSIM Life utilized its hybrid AI platform, BIOiSIM, to address the challenges of limited and missing data from clinical trials. The approach included imputing missing biomarker data utilizing hybrid AI models to reduce missing values with high robustness and enriching patient populations, including underrepresented groups, through AI-driven virtual patient generation (with 10,000 virtual patients generated). The use of such enriched data also allowed for the use of Explainable AI to identify the most important biomarkers - enabling accurate patient stratification. (119 words)
- [Verisimlife](/content/solutions/safety-toxicity-profiles/index.html) (1,176 words)
- [Verisimlife](/content/solutions/patient-stratification/index.html) (1,091 words)
- [Verisimlife](/content/solutions/drug-drug-interactions/index.html) (1,047 words)
- [Verisimlife](/content/solutions/formulation/index.html) (1,184 words)
- [Verisimlife](/content/solutions/drug-repurposing/index.html) (856 words)
- [Verisimlife](/content/solutions/ai-drug-discovery/index.html) (916 words)
- [Not Found](/content/media-coverage/new-tools-and-tougher-economics-will-define-drug-discovery-in-2026.html) (28 words)
- [VeriSIM Life Earns Frost & Sullivan Competitive Strategy Leadership Award for Best Practices in AI-enabled Preclinical Development Industry  │ Drug Discovery & Development Technology](/content/press-events/verisim-life-earns-frost-sullivan-competitive-strategy-leadership-award-for-best-practices-in-ai-enabled-preclinical-development-industry.html): Frost & Sullivan recently assessed the artificial intelligence (AI)-enabled preclinical development industry, and, based on its analysis results, recognizes VeriSIM Life with the 2022 North America Competitive Strategy Leadership Award. (850 words)
- [Verisimlife](/content/solutions/efficacy-predictions/index.html) (654 words)
- [VeriSIM Life and Total Brain Announce Strategic Collaboration Agreement Applying AI to Develop New Drugs for Neurological Disorders │ Drug Discovery & Development Technology](/content/press-events/total-brain-collaboration-applying-ai-to-develop-new-drugs-for-neurological-disorders.html): Partnership will pioneer the integration of Total Brain’s proprietary mental health and brain performance database with VeriSIM Life’s BIOiSIM™ platform (583 words)
- [VeriSIM Life Named “Predictive Analytics Solution of  the Year” by BioTech Breakthrough │ Drug Discovery & Development Technology](/content/press-events/verisim-life-named-predictive-analytics-solution-of-the-year-by-biotech-breakthrough.html): VeriSIM Life today announced it has been selected as the winner of the “Predictive Analytics Solution of the Year" in the BioTech Breakthrough Awards program conducted by BioTech Breakthrough. (632 words)
- [VeriSIM CEO Jo Varshney Selected Finalist for 2023 Stevie® Awards for Women in Business │ Drug Discovery & Development Technology](/content/press-events/verisim-ceo-jo-varshney-selected-finalist-for-2023-stevie-r-awards-for-women-in-business.html): SAN FRANCISCO, Sept. 25, 2023 /PRNewswire/ -- Jo Varshney, Founder and CEO of VeriSIM Life—developers of the world's first "credit score" for de-risking drug development— was announced as a finalist in the "Most Innovative Woman of the Year—Healthcare" category of the 20th annual Stevie® Awards for Women in Business. The Stevie Awards honor the world's top women entrepreneurs, executives, employees, and the organizations they run. (674 words)
- [Verisimlife](/content/miscellaneous/meet-with-us-at-jpm-2026/index.html) (313 words)
- [VeriSIM Preempting a Clinical Dead End with Metabolite Analysis Powered by Hybrid AI │ Drug Discovery & Development Technology](/content/case-studies/using-ai-ml-to-analyze-metabolites-and-determine-potential-success.html): Optimizing a drug candidate, even when demonstrating strong efficacy, can be a challenge when metabolites may be involved in creating the intended therapeutic effect. VeriSIM Life’s client needed to confirm their compound’s efficacy as direct or indirect and determine their best path forward for developing a novel cancer therapy. BIOiSIM confirmed a metabolite-driven mechanism of action, identified a range of efficacious metabolites, and ranked them based on both potency and safety. (86 words)
- [VeriSIM Life Earns "Predictive Analytics Solution of the Year" Recognition by BioTech Breakthrough Awards for Third Consecutive Year │ Drug Discovery & Development Technology](/content/press-events/verisim-life-earns-predictive-analytics-solution-of-the-year-recognition-by-biotech-breakthrough.html): Nov. 19, 2024 - VeriSIM Life today announced that its platform has once again been named "Predictive Analytics Solution of the Year" by the 2024 BioTech Breakthrough Awards. The company was first recognized in the same category in 2022, then again in 2023. The awards program is conducted by BioTech Breakthrough, a leading independent marketing intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products, and services around the globe. (474 words)
- [Jo Varshney, Founder and CEO of VeriSIM Life, Wins Gold in Annual Stevie® Awards for Women in Business │ Drug Discovery & Development Technology](/content/press-events/jo-varshney-founder-and-ceo-of-verisim-life-wins-gold-in-annual-stevie-r-awards-for-women-in-business.html): Dr. Jo Varshney, leader of artificial intelligence and machine learning drug development platform BIOiSIM, is recognized as Most Innovative Woman of the Year in the Stevie Awards Healthcare category. (665 words)
- [VeriSIM Frost & Sullivan Report: AI-enabled Preclinical Development, VeriSIM Life │ Drug Discovery & Development Technology](/content/case-studies/frost-sullivan-report-2022/index.html): Frost & Sullivan 2022 Competitive Strategy Leader Award North American Artificial Intelligence Enabled Preclinical Development Industry (103 words)
- [VeriSIM Life Awarded Federal Grant from National Institutes of Health for Substance Use Disorder Drug Discovery and Development │ Drug Discovery & Development Technology](/content/press-events/nih-grant-for-substance-use-disorder-drug-discovery-and-development.html): VeriSIM to share NIH Small Business Innovation Research (SBIR) grant to accelerate AI-driven drug discovery for substance use disorder (467 words)
- [VeriSIM Optimizing Dosing with AI/ML Driven Transdermal Drug Permeation Simulation │ Drug Discovery & Development Technology](/content/case-studies/transdermal-drug-delivery/index.html): This study covers the development and validation of a transdermal model using the BIOiSIM framework, which was further used to describe the relationship between compound exposure and therapeutic effect. (41 words)
- [VeriSIM Life Announces Collaboration with Mayo Clinic to Accelerate New Drug Development │ Drug Discovery & Development Technology](/content/press-events/verisim-life-announces-collaboration-with-mayo-clinic-to-accelerate-new-drug-development.html): SAN FRANCISCO, Oct. 1, 2024 /PRNewswire-PRWeb/ -- VeriSIM Life, a leader in AI-driven drug discovery and development, today announced its second collaboration agreement with Mayo Clinic, aimed at accelerating the development of new therapies for liver and metabolic diseases. The collaboration will leverage Mayo Clinic's extensive clinical and research expertise along with VeriSIM Life's pioneering AI-powered platform to address critical unmet medical needs. (441 words)
- [VeriSIM NIH Human-Based Research Toolkit: Unlocking Predictive Power, Reducing Costs, and Accelerating Translation │ Drug Discovery & Development Technology](/content/case-studies/nih-toolkit/index.html): The NIH’s groundbreaking shift to prioritize human-relevant science marks a paradigm change for biomedical research institutions. This toolkit outlines how VeriSIM Life’s BIOiSIM® platform enables researchers to align with NIH’s new direction, replacing traditional animal testing with predictive, clinically relevant AI-driven tools. For institutions, this shift doesn’t just improve science—it enhances funding competitiveness, reduces R&D costs, and accelerates translational impact. (160 words)
- [VeriSIM BIOiSIM™ Drug Decision Engine: Breakthrough Intelligence to De-risk R&D Translation, Without Disruption │ Drug Discovery & Development Technology](/content/case-studies/introducing-bioisim/index.html): This white paper showcases how fusing artificial intelligence and mechanistic modeling can be used to discover novel drugs and accurately predict the disposition of small molecules across different subjects for translation to clinical success. (49 words)
- [VeriSIM Predicting Translatable Drug Combinations for ADCs - A Pharma Partner Case Study │ Drug Discovery & Development Technology](/content/case-studies/predicting-drug-combinations-for-adcs-a-partner-case-study.html): VeriSIM Life investigated for our client Debiopharm a novel drug combination strategy that combines ADCs with current therapies to enhance their effectiveness in reducing tumor burden. Our hybrid AI computational platform, BIOiSIM®, ranked the predicted optimal combinations with regard to efficacy based on our multi-dimensional Translational Index™ technology. (64 words)
- [Verisimlife](/content/miscellaneous/meet-verisim-life-at-aacr-24-in-san-diego/index.html) (129 words)
- [VeriSIM Predicting Patient-Specific Drug Bioavailability with AI │ Drug Discovery & Development Technology](/content/case-studies/patient-stratification/index.html): This study covers one of the many applications of BIOiSIM. Our aim was to establish what the pharmacokinetic (PK) profile would look like in the different subjects studied. (37 words)
- [VeriSIM AtlasGen Novel Drug Designer: Design Clinical Success Into New Drug Discovery from Day One │ Drug Discovery & Development Technology](/content/case-studies/atlasgen-novel-drug-designer-white-paper/index.html): AtlasGEN efficiently identifies new molecules based on favorable chemical properties and simultaneously evaluates them for clinical safety and effectiveness based on biology using VeriSIM Life’s groundbreaking Translational Index™ technology. With AtlasGEN, pharmaceutical companies can take advantage of AI-driven drug design chemistry with biological validation to discover clinically successful novel therapies at the beginning of the drug design process. It reduces the time and cost associated with other computational hit discovery approaches, while compressing the hit-to-lead refinement and optimization process. Download the white paper to learn more. (103 words)
- [VeriSIM Complex Organ Toxicity: Hybrid AI Provides Superior Prediction Accuracy with Very Limited Data │ Drug Discovery & Development Technology](/content/case-studies/complex-organ-toxicity-hybrid-ai/index.html): Drug-induced liver injury (DILI) is a major concern in the pharmaceutical industry, accounting for a significant number of drug failures and withdrawals. Traditional ways to predict DILI rely a lot on animal studies and in vitro tests. These can take a long time, cost a lot, and often don't accurately predict human DILI. As a result, there is a growing interest in using computational approaches to predict DILI. However, these methods fail to adequately consider detailed aspects of interspecies differences in drug pharmacological behavior, gene dysregulation due to the drugs, accurate drug chemistry, and integration of specific liver toxicity pathways. VeriSIM Life performed research aimed to solve these problems by leveraging knowledge-AI hybrid technology (hybrid AI) to provide robust solutions even in severely data-limited scenarios. (141 words)
- [VeriSIM How to Evolve from Traditional Model-Informed Drug Discovery & Development to an AI-Informed Approach  │ Drug Discovery & Development Technology](/content/case-studies/ebook-how-to-evolve-to-an-ai-informed-approach/index.html): The purpose of this eBook is to demonstrate that an integrated MIDD+AI approach can assist with preclinical operations while minimizing disruption. In fact, experts currently using traditional R&D methods already have extensive knowledge and experience necessary to support the multidisciplinary harmonization of data needed to leverage integrated AI-enhanced MIDD frameworks and workflows. (87 words)
- [VeriSIM Life Announces Acquisition of Molomics Biotech │ Drug Discovery & Development Technology](/content/press-events/verisim-life-announces-acquisition-of-molomics-biotech.html): Molomics’ technology will seamlessly integrate into the BIOiSIM™ platform, to further improve success rates for the discovery, development and approval of new drugs for the most challenging diseases impacting humankind (322 words)
- [VeriSIM Life Awarded NIH Phase II STTR to Advance AI Driven Drug Discovery Platform │ Drug Discovery & Development Technology](/content/press-events/verisim-life-awarded-nih-phase-ii-sttr-to-advance-ai-driven-drug-discovery-platform.html): SAN FRANCISCO, Calif. — VeriSIM Life today announced it has been awarded a Phase II Small Business Technology Transfer (STTR) grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to advance its proprietary BIOiSIM® mechanistic AI platform for the discovery of novel therapeutics for stimulant use disorder. (351 words)
- [VeriSIM Life Announces Webinar on Mitigating Translational Risk in Drug Development with AI/ML  │ Drug Discovery & Development Technology](/content/press-events/verisim-life-announces-webinar-on-mitigating-translational-risk-in-drug-development-with-ai-ml.html): San Francisco, CA, May 9th, 2023 - VeriSIM Life (VeriSIM) www.verisimlife.com, the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced a webinar hosted by CEO and Founder Dr. Jo Varshney, PhD and Dr. Jeff Barrett, PhD, Chief Science Officer at Aridhia Digital Research Environment (https://www.aridhia.com). (325 words)
- [About us | Diversity, Inclusion, and Belonging |  VeriSIM Life](/content/about-us/index.html): A dedicated team of scientists, chemists & software engineers that are passionate about addressing the need for better prediction in healthcare. (1,386 words)
- [Welcome to BIOiSIMTM │ Drug Discovery & Development Technology](/content/our-platform/index.html): We provide technology enabled services to address your translational challenges guided by our unique Translational IndexTM capability. (1,163 words)
- [Clarivate Expands Partnership with VeriSIM Life to Accelerate and De-risk Research and Drug Development  │ Drug Discovery & Development Technology](/content/press-events/clarivate-expands-partnership-with-verisim-life-to-accelerate-and-de-risk-research-and-drug-development.html): New AI-enabled, integrated workflow provides pharma and biotech companies with comprehensive R&D insights to help minimize late-stage failures during clinical trials (802 words)
- [VeriSIM Press & Events │ Drug Discovery & Development Technology](/content/press-events/index.html): Events that talk about integration of Total Brain’s proprietary mental health & brain performance database with VeriSIM Life’s BIOiSIM™ platform (337 words)
- [Dr. Varshney Selected as Finalist for Executive Leader Award in Women in AI Awards North America 2025 │ Drug Discovery & Development Technology](/content/press-events/dr-varshney-selected-as-finalist-for-executive-leader-award-in-women-in-ai-awards-north-america-2025.html): San Francisco, California - March 18th, 2025 - VeriSIM Life is proud to announce that their CEO, Dr. Varshney, has been named a finalist for the 'Executive Leader Award - Woman Executive of the Year' in the Women in AI Awards North America 2025. This prestigious award recognizes outstanding leadership and significant contributions to the field of artificial intelligence. (512 words)
- [Media Coverage](/content/media-coverage/index.html): Events that talk about integration of Total Brain’s proprietary mental health & brain performance database with VeriSIM Life’s BIOiSIM™ platform (536 words)
- [Pillar - Versimlife](/content/pillar/index.html) (1,095 words)
- [Dr. Jo Varshney Named to List of Most Influential Women in Bay Area Business from the San Francisco Business Times │ Drug Discovery & Development Technology](/content/press-events/dr-jo-varshney-most-influential-women-in-bay-area-business.html): VeriSIM Life, the leading AI-enabled, R&D decisions de-risker for drug development, today announced its Founder and CEO, Dr. Jo Varshney, has been named to the San Francisco Business Times' 2024 list of Most Influential Women in Bay Area Business. Dr. Varshney was competitively selected from more than 400 nominees to be honored with this prestigious award for her successful leadership at VeriSIM Life and innovation in the biopharma industry. (663 words)
- [VeriSIM Life CEO Dr. Jo Varshney Wins Prestigious 2025 International Women Entrepreneur Award in Information Technology │ Drug Discovery & Development Technology](/content/press-events/dr-jo-varshney-wins-prestigious-2025-international-women-entrepreneur-award.html): San Francisco, CA — VeriSIM Life, with its leading AI-driven biosimulation platform transforming drug development, is proud to announce that its Founder and CEO, Dr. Jo Varshney, has been honored with the 2025 International Women Entrepreneur Award in IT by Great Companies. (328 words)
- [Five AI-enhanced clinical trial start-ups to watch in 2021 │ Drug Discovery & Development Technology](/content/press-events/five-ai-enhanced-clinical-trial-start-ups-to-watch-in-2021.html) (10 words)
- [Regulatory Resources](/content/regulatory-resources/index.html) (915 words)
- [VeriSIM Life Enters into Collaboration Agreement with Mayo Clinic to Jointly Advance Drug Discovery and Development Programs │ Drug Discovery & Development Technology](/content/press-events/collaboration-agreement-with-mayo-clinic/index.html): Collaboration to reduce the number of outsourced preclinical experiments and help de-risk R&D decisions early-on to ensure expedited development of novel, safe and highly efficacious drugs (427 words)
- [Home (New)](/content/home-new/index.html) (94 words)
- [VeriSIM Videos │ Drug Discovery & Development Technology](/content/videos/index.html): AI in Drug Development: Hype or Reality? Introducing VeriSIM Life, Intel Capital Interview with VeriSIM Life CEO Jo Varshney (494 words)
- [VeriSIM Case Studies & White Papers │ Drug Discovery & Development Technology](/content/case-studies/index.html): This studies and white papers covers many applications of BIOiSIM, Optimizing Stratified Dosing  simulation of drug disposition & more (842 words)
- [VeriSIM Testimonials │ Drug Discovery & Development Technology](/content/testimonials/index.html): We are proud to have satisfied customers advancing drug development and treatment worldwide. (616 words)
- [Our Pipeline](/content/our-pipeline/index.html) (125 words)
- [VeriSIM Publications │ Drug Discovery & Development Technology](/content/publications/index.html): Browse our educational blog posts on topics related to drug discovery and development, as well as our scholarly and peer-reviewed research. (288 words)
- [VeriSIM Careers  │ Drug Discovery & Development Technology](/content/careers/index.html): We offer Medical, Dental, Vision, and Commuter Benefits in addition to unlimited vacation & catered lunches at least once per week. (347 words)
- [Thank You - VeriSIM Life | Drug Discovery & Development Technology](/content/thank-you/index.html): Thanks for submitting the form. Your case study will be sent in an email from VeriSIM Life. (33 words)
- [Privacy Policy │ Drug Discovery & Development Technology](/content/privacy/index.html): VeriSIM Life Website Privacy Policy, Learn more (1,018 words)
- [Molomics │ Drug Discovery & Development Technology](/content/molomics/index.html): Molomics is now a part of VeriSIM Life (52 words)
- [VeriSIM Book demo │ Drug Discovery & Development Technology](/content/book-demo/index.html): Book a Demo to Explore the Software of VeriSIM Life (46 words)
- [test](/content/test/index.html) (86 words)

## Listings & Categories

- [VeriSIM Publications  │ Drug Discovery & Development Technology](/content/archive/publications/index.html): Browse our educational blog posts on topics related to drug discovery and development, as well as our scholarly and peer-reviewed research. (266 words)
- [VeriSIM Blog │ Drug Discovery & Development Technology](/content/archive/blog/index.html): Browse our educational blog posts on topics related to drug discovery and development, as well as our scholarly and peer-reviewed research. (314 words)

## About Pages

- [VeriSIM Contact │ Drug Discovery & Development Technology](/content/contact/index.html): Don't hesitate to get in touch. Whatever your goal, let’s chat about how to get you there. (25 words)

## Resources

- [Full Page Index](/index.html): Browse all cached pages with rich metadata
- [About This Cache](/content/about.html): Methodology, technical details, and usage guidelines
- [XML Sitemap](/sitemap.xml): Machine-readable sitemap for crawler discovery
- [Robots.txt](/robots.txt): Crawler directives